Mosaic loss of chromosome Y (mLOY) leading to gonosomal XY/XO commonly occurs during aging, particularly in smokers. We investigated whether mLOY was associated with non-hematological cancer in three prospective cohorts (8,679 cancer cases and 5,110 cancer-free controls) and genetic susceptibility to mLOY. Overall, mLOY was observed in 7% of men, and its prevalence increased with age (per-year odds ratio (OR) = 1.13, 95% confidence interval (CI) = 1.12-1.15; P < 2 × 10 −16 ), reaching 18.7% among men over 80 years old. mLOY was associated with current smoking (OR = 2.35, 95% CI = 1.82-3.03; P = 5.55 × 10 −11 ), but the association weakened with years after cessation. mLOY was not consistently associated with overall or specific cancer risk (for example, bladder, lung or prostate cancer) nor with cancer survival after diagnosis (multivariate-adjusted hazard ratio = 0.87, 95% CI = 0.73-1.04; P = 0.12). In a genome-wide association study, we observed the first example of a common susceptibility locus for genetic mosaicism, specifically mLOY, which maps to TCL1A at 14q32.13, marked by rs2887399 (OR = 1.55, 95% CI = 1.36-1.78; P = 1.37 × 10 −10 ). mLOY refers to loss of the Y chromosome in a subset of cells while the remainder of cells retain the normal chromosome. For more than four decades, it has been noted that a fraction of healthy men lose all or some portion of the Y chromosome over the course of their lifetime 1 . Moreover, several studies have reported mLOY in males of advanced age, suggesting that mLOY is associated with aging and increasing hypodiploidy [1] [2] [3] [4] . Other studies have suggested that mLOY is associated with specific hematological disorders, including acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS) and preleukemia [5] [6] [7] [8] [9] .
SNP genotyping arrays have become an important tool for discovering common variants that contribute to human diseases 10 . Two widely used applications of this technology are genome-wide association studies (GWAS) and copy number variant (CNV) analyses for large-scale mosaic autosomal aberrations [11] [12] [13] [14] [15] [16] [17] [18] . SNP microarray data have also been used to investigate mosaicism on the sex chromosomes 19, 20 . Other studies have evaluated next-generation sequencing data to detect mosaic mutations at the base-pair level [21] [22] [23] . Although each of these studies of mosaic CNVs, mosaic uniparental disomies, mosaic single-nucleotide variants (SNVs) and mLOY ascertain different aspects of the biological process of clonal expansion, taken together, these studies suggest that the frequency of mosaic eventsboth large and small-increases with age. This trend could reflect either a deterioration in the capacity to maintain a stable genome or, alternatively, a decline in stem cell diversity [22] [23] [24] [25] .
We investigated the association between mLOY and age at DNA collection, smoking status, DNA source (derived from blood or buccal material), inferred ancestry, genetic susceptibility to mLOY, non-hematological cancer risk and cancer-specific survival in subjects from three prospective cohorts: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial (PLCO) and the Cancer Prevention Mosaic loss of chromosome Y is associated with common variation near TCL1A l e t t e r s Table 1 ). SNP microarray data generated using Illumina Infinium arrays for GWAS that had sufficient coverage of the Y chromosome (Human Hap610K, Hap1M, Omni1M and Omni2.5M arrays) were used to detect mLOY in DNA isolated from blood or buccal cells for 8,679 males with non-hematological cancer and 5,110 cancer-free adult male controls. The hybridization data from all subjects were examined for deviations from the expected log 2 -transofmred intensity ratio (Online Methods) representing evidence of loss or gain of the male-specific region of chromosome Y (MSY; chr. Y: 6,671,498-22,919,969, hg18/Build 36) (Supplementary Fig. 1a) . We observed 970 men (7.03%) with detectable mLOY, and the estimated fraction of affected cells was 22.7-73.4% (Online Methods and Supplementary Fig. 1c ), which differs from the fraction for autosomes (7-95% mosaicism 14, 15 ). No significant difference in mLOY frequency was observed when adjusting for DNA source, either blood or buccal (P = 0.33), or by genotyping array (P = 0.14; Supplementary Table 2) .
Study II (CPS-II) (Supplementary
We validated the accuracy of our mLOY detection method by qPCR analysis of markers for 15 genes distributed across the MSY (Supplementary Fig. 1b) 26 . We selected 124 subjects from the cohorts with probable mLOY for validation by qPCR assays. The concordance rate between the SNP microarrays and qPCR was 87.9% (Supplementary  Table 3) , with no differences observed by array type.
Among the 13,789 males scanned, we found evidence of chromosome Y gain for 133 males (0.96%). For the males with suspected chromosome Y gain, we had DNA available from 69 individuals for qPCR validation. The concordance rate was only 49% for mosaic gains (Supplementary Table 3) , with validation corresponding to substantial log R ratio (LRR) deviation from baseline. After removing 34 men with validated chromosome Y gain, we excluded 26 participants with similarly large positive deviations from the baseline after manual review. The resulting data set included 8,632 cancer cases and 5,097 controls for analysis of chromosome Y loss. Of the 8,632 cases, 5,545 had their blood or buccal cells collected at least 1 year before cancer diagnosis. The majority of these participants (n = 5,369) were diagnosed with bladder, lung or prostate cancer.
The most significant association for mLOY was with increasing age: in 13,729 men, the frequency of detectable mLOY increased from 1.18% for men under 60 years of age to 18.71% for men over 80 years of age. The proportion of individuals with mLOY increased for every age stratum up to 80 years of age (P < 2.2 × 10 −16 ); for older participants, the estimates became less stable because of the small numbers of subjects (Fig. 1a,b and Supplementary Table 4). Adjusting for smoking status (current smoking and, for former smokers, years since cessation), ancestry, source of DNA and contributing study, we observed evidence for an association between mLOY and age (OR per year of age = 1.13, 95% CI = 1.12-1.15; P < 2.00 × 10 −16 ) ( Age refers to the age at DNA collection, and the odds ratio estimate is for a 1-year increase in age. For the association between age and mLOY, the analysis was adjusted for smoking status (current smoking and, for former smokers, the number of years since cessation), estimated admixture proportion, DNA source and contributing study. For the association between mLOY and the number of years since cessation and the number of cigarettes smoked per day, the analyses were adjusted for age, estimated admixture proportion, DNA source and contributing study.
npg l e t t e r s autosomal mosaic events (OR = 1.05, 95% CI = 1.04-1.07) 15 and for mosaic SNVs (OR = 1.08, 95% CI = 1.07-1.09) 22 . The frequency of individuals exhibiting age-related mLOY was nearly tenfold greater than that observed for autosomal mosaicism (0.7-2.0%) [14] [15] [16] . A detectable mosaic autosomal abnormality (>2 Mb in length) was observed in 130 (0.95%) men 16 . This rate is substantially lower than what was observed for mLOY in the same individuals (7.07%), indicating that mLOY is the most frequent large-scale chromosomal somatic event. Of the 970 males in our study with mLOY, 18 (1.86%) also had evidence of detectable autosomal mosaicism (Supplementary Tables 6 and 7), suggesting that men with mLOY are more likely to harbor large autosomal mosaic events than men without mLOY (OR = 2.13, 95% CI = 1.22-3.55; P = 0.005).
We investigated the association with smoking status in 9,859 subjects (1,034 current smokers, 5,410 former smokers, 3,408 never-smokers and 7 individuals of unknown status) from the PLCO and CPS-II studies, excluding participants from ATBC, which recruited only current smokers. The frequency of mLOY was higher in ever-smokers (65.4%) than in never-smokers (34.6%), with the highest frequency among current smokers. Relative to never-smokers who were less than 65 years old, current smokers over 75 years old had increased risk of mLOY (OR = 13.9, 95% CI = 6.60-29.26; P = 4.13 × 10 −12 ) ( Fig. 2a and Supplementary Table 8) . Adjusting for age, ancestry, DNA source and study, we observed an association of mLOY with current smoking (OR = 2.35, 95% CI = 1.82-3.03; P = 5.55 × 10 −11 ) and former smoking (OR = 1.33, 95% CI = 1.12-1.57; P = 0.001) ( Table 1 and  Supplementary Table 9 ). This result is consistent with a previous report that men who smoke are at greater risk of mLOY, with observed odds ratios for current smoking versus non-smoking that ranged from 2.4 (95% CI = 1.6-3.6) to 4.3 (95% CI = 2.8-6.7) 19 for the three studies included. Mosaic SNVs have also been associated with smoking with comparable odds ratio estimates (OR = 2.2) 23 . It is notable that previous studies have not reported an association between smoking and large-scale (>2-Mb) autosomal mosaicism 14, 15 .
Because of differences in mLOY between current and former smokers, the risk of mLOY progressively declined with increasing number of years after cessation, with OR = 2.15 within 1-4 years of quitting (95% CI = 1.49-3.10; P = 3.83 × 10 −5 ), OR = 1.92 within 5-10 years of quitting (95% CI = 1.43-2.58; P = 1.26 × 10 −5 ) and OR = 1.49 within 11-20 years of quitting (95% CI = 1.17-1.90; P = 0.001) relative to never smoking. By 20 years after cessation, there was no evidence for association (OR = 1.10, 95% CI = 0.91-1.34, P = 0.33) (Fig. 2b , Table 1 and Supplementary Table 10 ). Our findings suggest that smoking has a long-lasting impact on mLOY, influencing its frequency perhaps more than a decade after quitting, but the association wanes with long-term cessation. Among 4,904 current smokers, we observed no association of mLOY with smoking intensity, measured by cigarettes per day ( Table 1 and Supplementary Table 11) .
It has been proposed that autosomal mosaicism may be associated with risk for certain solid tumors, but a connection has not been definitely established [14] [15] [16] . Moreover, others have suggested that mLOY is associated with cancer risk overall 20 . We investigated the frequency of mLOY in blood or buccal DNA and solid tumor risk in 5,545 subjects with cancer from whom DNA was collected at least 1 year before cancer diagnosis and in 5,097 cancer-free individuals (Supplementary Table 12 ). Overall, mLOY was slightly more common in men who went on to develop cancer (6.67%) than in cancerfree controls (5.49%) (unadjusted OR = 1.23, 95% CI = 1.04-1.45; P = 0.012; multivariate-adjusted OR = 1.19, 95% CI = 1.00-1.42; P = 0.047) ( Table 2, Supplementary Fig. 2 and Supplementary  Table 13 ). Furthermore, we investigated a possible association between cancer risk and mLOY for cancer types with sufficient sample size, including bladder, lung and prostate cancers in adjusted analyses (using continuous age, smoking status (current smoking and, for former smokers, years since quitting), ancestry, source of DNA and study). In the cohort studies with DNA collected 1 year or more before cancer diagnosis, we observed a possible association between mLOY and risk of bladder cancer (OR = 1.47, 95% CI = 1.09-1.99; P = 0.011) and risk of prostate cancer (OR = 1.35, 95% CI = 1.04-1.74; P = 0.024) but no evidence for a relationship with lung cancer (OR = 0.90, 95% CI = 0.69-1.18, P = 0.45) ( Table 2 ). This latter point is striking given that lung cancer is more strongly associated with smoking than either bladder or prostate cancer. We examined cases diagnosed at or before The analysis used mLOY as the predictor variable and cancer type as the response variable and was adjusted for continuous age, smoking status (current smoking and, for former smokers, the number of years since cessation), estimated admixture proportion, DNA source and contributing study. A total of 5,097 cancer-free controls were used as a reference.
Other cancers in addition to bladder, lung and prostate cancers were included when performing the combined cancer analysis. Table 14) . Together, these results provide limited support for the hypothesis that mLOY is a strong risk factor for common solid tumors, and larger studies will be needed to investigate further given the current estimated effect sizes. A recent report suggested that mLOY was associated with all-cause and cancer-related mortality in a cohort of 982 participants who were free from cancer at the study baseline 20 . As cancer mortality reflects both developing cancer and dying from it, we examined whether mLOY might be associated with subsequent overall and cancer-specific mortality in our cancer cases, restricting our analysis to cases with DNA collected at least 1 year before diagnosis and available followup (n = 5,340). We observed little evidence for an association with either end point, whether in Kaplan-Meier survival curves (Fig. 3a,b) or in unadjusted or multivariate-adjusted Cox proportional hazard models (Supplementary Table 15) . After adjusting for age at diagnosis, smoking status (current smokers and, for former smokers, the number of years since cessation), smoking intensity in pack-years, body mass index (BMI) and contributing study, the hazard ratio for mortality from all causes was 0.89 (95% CI = 0.76-1.04; P = 0.15) and the hazard ratio for mortality from cancer was 0.87 (95% CI = 0.73-1.04; P = 0.12). Similar findings were observed for bladder, lung and prostate cancers separately (Fig. 3c-e and Supplementary  Table 15) .
We conducted a GWAS to identify regions associated with risk for mLOY in the three cohorts, analyzed separately and in a meta-analysis. We adjusted for smoking status (ever-versus never-smoker) and principal components significantly associated with mLOY in each cohort (P < 0.05; reported previously to account for subtle differences in population substructure in participants of European background). The analysis included 895 men with detected mLOY and 11,474 men with no detected mLOY. The P-value distribution from the combined meta-analysis had an inflation factor (λ) of 1.015, as depicted in the quantile-quantile plot (Supplementary Fig. 3 ). We observed a significant association with SNP rs2887399 at 14q32.13 (OR = 1.55, 95% CI = 1.36-1.78; P = 1.37 × 10 −10 ) (Fig. 4 and Supplementary Fig. 4) . The major risk allele (G) has a frequency of 0.77 in the CEU (Europeanancestry) population. The effect estimates were consistent across the three studies, and there was no evidence for heterogeneity (P = 0.86; Supplementary Fig. 5 ). The relationship remained robust when not adjusting for smoking status (OR = 1.57, 95% CI = 1.36-1.80; P = 6.46 × 10 −11 ). The rs2887399 variant maps to the 5′ end of the TCL1A gene (encoding T cell leukemia/lymphoma 1A), which functions as a co-activator of the cell survival kinase AKT and has been implicated in T cell and B cell hematological malignancies 27 , mainly because recurrent chromosomal rearrangements bring TCL1A in close proximity to the T cell antigen receptor gene 28 . To our knowledge, the rs2887399 variant is the first common variant associated with a clonal expansion phenotype beyond the known association of a JAK2 haplotype with mosaicism for the common JAK2 variant encoding p.Val617Phe (refs. 29-32) . This genetic finding linking germline variation to somatic mosaicism could lead to an understanding of how clonal hematopoiesis relates to many chronic diseases; it is plausible that the susceptibility haplotype could contribute to actual loss of the Y chromosome or that it could be permissive for clonal expansion. Further work is needed to fine-map the region and investigate its biological underpinnings of the development of mLOY.
In summary, mLOY is the most common large-scale detectable mosaic chromosomal event in males, and it has a striking association with aging and cigarette smoking, which is attenuated by years after cessation. We observed limited evidence for mLOY as a strong risk factor for three common cancer types in men, and we did not observe an association with survival after cancer diagnosis. Contrary to previous evidence suggesting that men with mLOY have a substantially higher likelihood of dying from cancer, our study provides little evidence for this hypothesis. Together, these data suggest that age and smoking have a substantial effect on the development of mLOY npg l e t t e r s but that there is insufficient evidence to conclude that mLOY is a major risk factor for non-hematological cancer in men. Lastly, our GWAS identified a locus at 14q32.13 associated with mLOY, which may provide insight into the biological basis of mLOY in relation to smoking and aging in men.
MethOds
Methods and any associated references are available in the online version of the paper.
Accession codes.
A complete list of the mLOY events identified in this study is provided as the Supplementary Data Set.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINe MethOds
Study overview. The analyzed data consist of 13,789 males drawn from cancer GWAS conducted in three prospective cohorts. The mean age at DNA collection was 67.26 years for all participants. The studies were approved by the institutional ethics committee of each participating hospital and the Institutional Review Board (IRB) of the National Cancer Institute. Written informed consent was obtained from all individuals. DNA was extracted from peripheral circulating leukocytes (70.38%) and buccal samples (29.62%) for men drawn from the three cohorts (Supplementary Table 1 ). Genomic DNA was screened and analyzed at the National Cancer Institute according to the standard sample handling process of the Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and Genetics (DCEG). AmpFlSTR Identifiler assays confirmed that each sample was concordant with reported sex and removed samples with evidence of contamination. Genotyping was carried out on one of four Illumina Infinium SNP arrays (Human Hap610K, Hap1m, Omni1M and Omni2.5M arrays), each of which has an adequate number of probes specific to the Y chromosome. Additional scanning on other microarray chips was not used because of the inadequate probe coverage for the Y chromosome. Of all the participants, 94.99% were detected as having ≥80% European ancestry and 2.39% were detected as having ≥80% African ancestry. Case-control studies for bladder cancer were also included and were drawn from two studies carried out in Spain and the New England Bladder Cancer Study, previously scanned with the Human Hap1M and Hap610K chips 34 , respectively. The MD Anderson bladder cancer study was initially scanned on a chip with inadequate probe coverage for the Y chromosome 35 , and we therefore detected mLOY in this study using the qPCR assay described below (Supplementary Table 14) .
Analysis of log 2 -transformed intensity ratio and B allele frequency generation. Sample intensity files (two files per sample, for the red and green channels) were loaded into Illumina GenomeStudio software. The intensity data were normalized using the Illumina five-step self-normalization procedures, which used information contained on the array itself to convert raw x and y (allele A and allele B) signal intensities to normalized values. The LRR and B allele frequency (BAF) values for each assay were exported from GenomeStudio software using the Genotype Final Report (GFR) format.
Test region for detecting chromosome Y abnormality. We extensively examined loci across the Y chromosome for the four commercial chip types with adequate chromosome Y coverage and used the MSY from 6,671, 498-22,919,969 (hg18/Build 36) as the test region for detecting chromosome Y mosaicism, as this region provides relatively stable signal intensity and is outside of a majority of the regions containing genes with multiple copies 26 ( Supplementary Fig. 1a ).
Chromosome Y mosaicism detection method. Chromosome Y mosaicism was detected using LRR, which is the normalized measure of total signal intensity and provides data on relative copy number. Subjects were examined for deviations from the expected log 2 -transformed intensity ratio for evidence of loss of the MSY. A minimum mean threshold of LRR ≤−0.15 was used to identify a chromosome Y loss event. A minimum mean threshold of LRR ≥0.15 was used to define a chromosome Y gain event. Samples with mean LRR values falling below or above these thresholds were called as mosaic chromosome Y losses and gains, respectively. To minimize false discovery of chromosome Y mosaicism, the ratio of the mean LRR to the standard deviation for the test region was calculated. A minimum threshold for the ratio was set to 0.25 to filter out samples with excessive noise in their LRR values. For potential mLOY, each chromosome Y plot was manually reviewed and suspect events were further excluded in subsequent analyses. qPCR validation. qPCR was used to evaluate the ratio of chromosome Y signal to the signal for an autosomal single-copy gene. Fifteen qPCR gene assays spanning the p and q arms of the Y chromosome (Supplementary Fig. 1b) were run in duplex with RPPH1 (RNase P) as the reference gene, known to be single copy 26 (Supplementary Table 16 ).
For each sample, 5 ng of DNA, as determined by Quant-iT PicoGreen dsDNA quantification (Life Technologies), was transferred to a LightCycler-compatible 384-well plate (Roche) and dried down. An internal standard curve (comprising a serial dilution, with seven target ratios, of pooled male genomic DNA samples with no detectable chromosome Y loss, with a pool of female genomic DNA samples) and assay control samples (three target ratios; prepared similarly to the standard curve) were applied to the assay plates to guide analysis and indicate the overall quality of assay performance. All experimental and control samples were assayed in triplicate on each plate.
PCR was performed using a 5-µl reaction volume consisting of 2. LightCycler software (release 1.5.0) was used for initial analysis of raw data. Using absolute quantification analysis with the second-derivative maximum method and high-confidence detection algorithm, single target sequences were quantified and values were expressed as a ratio (target/reference) based on the internal standard curve of known ratios. The ratios of the 15 assays were averaged to yield an overall chromosome Y signal ratio.
Estimation of the proportion of cells with chromosome Y loss. A quadratic regression model was used to fit the average qPCR ratio and mean LRR data pairs, with mean LRR as the predictor variable (x) and average qPCR ratio as the response variable (y), to create a predictive polynomial equation y = a 0 + a 1 × x + a 2 × x 2 , where a 0 , a 1 and a 2 represent coefficient estimates. Only the data points from subjects having consensus event calls between qPCR and chip data for chromosome Y loss and normal, with coefficient of variation (CV) ≤10% from qPCR data, were used to generate such relationships (n = 98 subjects). For qPCR, the standard curve used simulates known ratios for the Y chromosome ranging from 10% to 100% (corresponding to 90% and no loss, respectively). This is achieved by diluting a pool of male samples with no mLOY with a pool of female samples to simulate these percentages of loss. Data for chromosome Y gain were not included when building the predictive model, as the qPCR ratio for the estimated amount of gain was not precise because the data were extrapolated outside the experimental copy number range of 0.1 to 1 defined by the standard curve. For each mean LRR, the corresponding copy number can be predicted by inserting the mean LRR into the quadratic equation. The percentage of cells with chromosome Y loss equals 1 minus the average chromosome Y signal ratio ( Supplementary Fig. 1c) ; for example, a mean LRR of −0.15 corresponds to a frequency of chromosome Y loss of 22.7%. We also performed this analysis for the case-control studies and found similar results (data not shown).
Logistic regression analysis. All of the logistic regression models were generated in R using the glm function with quasi-binomial family and logit as a link function. To determine the relationship between individuals with chromosome Y loss and their age at DNA collection, smoking behavior, DNA source, ancestry and study cohort, we fit several models that regressed the presence of chromosome Y loss for each individual on relevant covariates in a logistic model. To determine the relationship between individuals with chromosome Y loss and cancer diagnosis, we fit several models that regressed the occurrence of a cancer diagnosis for each individual on relevant covariates in a logistic model. The following covariate terms were defined for each individual: (i) age of DNA (a continuous measure of age at DNA collection); (ii-a) smoking status (a categorical variable with three levels: current smoker, former smoker and never-smoker (reference group)); (ii-b) number of years since cessation of smoking (a categorical variable with six levels: current smoker, 1-4 years, 5-10 years, 11-20 years and >20 years since quitting smoking, and never-smoker (reference group)); (iii) DNA source (a categorical variable with two levels: individuals who contributed DNA derived from a buccal sample and from a blood sample (reference group)); (iv) East Asian ancestry (a continuous measure of admixture estimation); (v) African ancestry (a continuous measure of npg
